2,3-diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 7, 1999, Pages 1274-1281

  Black, W Cameron ^a   Brideau, Christine ^a   Chan, Chi Chung ^a   Charleson, Stella ^a   Chauret, Nathalie ^a   Claveau, David ^a   Ethier, Diane ^a   Gordon, Robert ^a   Greig, Gillian ^a   Guay, Jocelyne ^a   Hughes, Gregory ^a   Jolicoeur, Paule ^a   Leblanc, Yves ^a   Nicoll Griffith, Deborah ^a   Ouimet, Nathalie ^a   Riendeau, Denis ^a   Visco, Denise ^b   Wang, Zhaoyin ^a   Xu, Lijing ^a   Prasit, Petpiboon ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPENTENONE DERIVATIVE; L 776967; L 784506; PHENYL GROUP; PYRIDINE DERIVATIVE; ROFECOXIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CELL PROTECTION; ENZYME INHIBITION; HYPOTHESIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANALGESICS, NON-NARCOTIC; ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL AVAILABILITY; CARRAGEENAN; CELL LINE; CHO CELLS; CRICETINAE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYCLOPENTANES; DIGESTIVE SYSTEM; EDEMA; FEMALE; FEVER; HUMANS; HYPERALGESIA; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICROSOMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TRANSFECTION;

EID: 0033535523     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980642l     Document Type: Article

References (35)

1. (a) Hla, T.; Neilson, K. Human Cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7384.
2. (b) Holtzman, M. J.; Turk, J.; Shornick, L. P. Identification of a Pharmacologically Distinct Prostaglandin H Synthase in Cultured Epithelial Cells. J. Biol. Chem. 1992, 267, 21438.
3. (c) Herschman, H. R. Regulation of Prostaglandin Synthase-1 and Prostaglandin Synthase-2. Cancer Metastasis Rev. 1994, 13, 241.
4. (a) Kennedy, B. P.; Chan, C.-C.; Culp, S. A.; Cromlish, W. A. Cloning and Expression of Rat Prostaglandin Endoperoxide Synthase (Cyclooxygenase)-2 cDNA. Biochem. Biophys. Res. Commun. 1993, 197, 494.
5. (b) Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Leahy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective Inhibition of Inducible Cyclooxygenase 2 in vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3228.
6. (c) Vane, J. R.; Mitchell, J. A.; Appleton, I.; Tomlinson, A.; Bishop-Bailey, D.; Croxtall, J.; Willoughby, D. A. Inducible Isoforms of Cyclooxygenase and Nitric-Oxide Synthase in Inflammation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2046.
7. (d) Harada, Y.; Hatanaka, K.; Saito, M.; Majima, M.; Ogino, M.; Kawamura, M.; Ohno, T.; Yang, Q.; Katori, M.; Yamamoto, S. Detection of Inducible Prostaglandin H Synthase-2 in Cells in the Exudate of Rat Carrageenan Induced Pleurisy. Biomed. Res. 1994, 15, 127-130.
8. Cryer, B.; Feldman, M. Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Antiinflammatory Drugs. Am. J. Med. 1998, 104, 413-421.
9. (a) Graul, A.; Martel, A. M.; Castaner, J. Celecoxib. Drugs Future 1997, 22, 711-714.
10. (b) Lanza, F.; Simon, T.; Quan, H.; Bolognese, J.; Rack, M. F.; Hoover, M.; Wilson, F. Selective Inhibition of Cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is Associated with Less Gastroduodenal Damage than Aspirin (ASA) 650 mg q.i.d. or Ibuprofen (IBU) 800 mg t.i.d. Meeting of the American Gastroenterological Association, Washington, DC, May 1997; Abstract 395.
11. (a) Riendeau, D.; Percival, M. D.; Boyce, S.; Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Falgueyret, J.-P.; Ford-Hutchinson, A. W.; Gordon, R.; Greig, G.; Gresser, M.; Guay, J.; Kargman, S.; Léger, S.; Mancini, J. A.; O'Neill, G.; Ouellet, M.; Rodger, I. W.; Thérien, M.; Wang, Z.; Webb, J. K.; Wong, E.; Xu, L.; Young, R. N.; Zamboni, R.; Prasit, P.; Chan, C.-C. Biochemical and Pharmacological Profile of a Tetrasubstituted Furanone as a Highly Selective COX-2 Inhibitor. Br. J. Pharmacol. 1997, 121, 105-117.
12. (b) Gauthier, J. Y.; Leblanc, Y.; Black, W. C.; Chan, C.-C.; Cromlish, W.; Gordon, R.; Kennedy, B. P.; Lau, C. K.; Léger, S.; Wang, Z.; Ethier, D.; Guay, J.; Mancini, J.; Riendeau, D.; Tagari, P.; Vickers, P.; Wong, E.; Xu, L.; Prasit, P. Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 Inhibitors. Part II: Replacing the Heterocycle. Bioorg. Med. Chem. Lett. 1996, 6, 87-92.
13. (a) Khanna, I. K.; Weier, R. M.; Yu, Y.; Collins, P. W.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2. J. Med. Chem. 1997, 40, 1619-1633.
14. (b) Li, J. J.; Norton, M. D.; Reinhard, E. J.; Anderson, G. D.; Gregory, S. A.; Isakson, P. C.; Kodboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Seibert, K.; Zhang, Y.; Zweifel, B. S.; Reitz, D. B. Novel Terphenyls as Selective Cyclooxygenase-2 Inhibitors and Orally Active Antiinflammatory Agents. J. Med. Chem. 1996, 39, 1846-1856.
15. (c) Huang, H.-C.; Li, J. J.; Garland, D. J.; Chamberlain, T. S.; Reinhard, E. J.; Manning, R. E.; Seibert, K.; Koboldt, C. M.; Gregory, S. A.; Anderson, G. D.; Veenhuizen, A. W.; Zhang, Y.; Perkins, W. E.; Burton, E. G.; Cogburn, J. N.; Isakson, P. C.; Reitz, D. B. Diarylspiro[2.4]heptenes as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors: Synthesis and Structure-Activity Relationships. J. Med. Chem. 1997, 39, 2253-2266.
16. (d) Khanna, I. K.; Weier, R. M.; Yu, Y.; Xu, X. D.; Koszyk, F. J.; Collins, P. W.; Koboldt, C. M.; Veenhuizen, A. W.; Perkins, W. E.; Casler, J.; Masferrer, J. L.; Zhang, Y. Y.; Gregory, S. A.; Seibert, K.; Isakson, P. C. 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents. J. Med. Chem. 1997, 40, 1634-1647.
17. (e) Wilkerson, W. W.; Copeland, R. A.; Covington, M.; Trzaskos, J. M. Antiinflammatory 4,5-Diarylpyrroles. 2. Activity as a Function of Cyclooxygenase-2 Inhibition. J. Med. Chem. 1995, 38, 3895-3901.
18. (a) Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O'Neil, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Thérien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. Rofecoxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: The Discovery of a Specific and Orally Active Cyclooxygenase-2 Inhibitor. Unpublished results.
19. (b) Chan, C.-C.; Brideau, C.; Gordon, R.; Xu, L.-J.; Tagari, P.; Ethier, D.; Guay, J.; Charleson, S.; Cromlish, W.; Kennedy, B.; Kargman, S.; O'Neill, G. P.; Mancini, J.; Wong, E.; Percival, M. D.; Ouellet, M.; Vickers, P.; Boyce, S.; Rupniak, N.; Visco, D.; Forrest, M. J.; Patrick, D.; Prasit, P.; Wang, Z.; Therien, M.; Leger, S.; Perrier, H.; Leblanc, Y.; Gauthier, J. Y.; Zamboni, R.; Young, R. N.; Rodger, I.; Gresser, M.; Ford-Hutchinson, A. W.; Riendeau, D. Rofecoxib, (Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)furanone): a Potent, Highly Specific and Orally Active Cyclooxygenase-2 Inhibitor - Pharmacological and Biochemical Profiles. J. Pharmacol. Exp. Ther. 1999, in press.
20. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. M.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazaole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
21. (a) Blacklock, T. J.; Butcher, J. W.; Sohar, P.; Lamanec, T. R.; Grabowski, E. J. J. A Versatile Synthesis of 1,1-Dioxo 7-Substituted Cephems: Preparation of the Human Leukocyte Elastase (HLE) Inhibitor 1,1-Dioxo-trans-7-methoxycephalosporanic Acid tert-Butyl Ester. J. Org. Chem. 1989, 54, 3907-3913.
22. (b) Schultz, H. S.; Freyermüth, H. B.; Buc, S. R. New Catalysts for the Oxidation of Sulfides to Sulfones with Hydrogen Peroxide. J. Org. Chem. 1963, 28, 1140-1143.
23. Schultz, A. G.; Lucci, R. D.; Fu, W. Y.; Berger, M. H.; Erhardt, J.; Hagmann, W. K. Heteroatom Directed Photoarylation. Synthetic Potential of the Heteroatom Oxygen. J. Am. Chem. Soc., 1978, 100, 2150-2162.
24. Stetter, H.; Schlenker, W. Addition von Aldehyden an Aktivierte Doppelbindungen, XXVII. Mitteilung: ein Einfacher weg zu 2-Hydroxy-cyclopentenonen. Tetrahedron Lett. 1980, 21, 3479-3482.
25. Kargman, S.; Wong, E.; Greig, G.; Falgueyret, J.-P.; Cromlish, W.; Ethier, D.; Yergey, J.; Riendeau, D.; Evan, J.; Kennedy, B.; Tagari, P.; Francis, D.; O'Neill, G. P. The Mechanism of Selective Inhibition of Human Prostaglandin G/H synthase-1 and -2 in Intact Cells. Biochem. Pharmacol. 1996, 52, 1113.
26. Riendeau, D.; Charleson, S.; Cromlish, W.; Mancini, J. A.; Wong, E.; Guay, J. Comparison of the Cyclooxygenase-1 Inhibitory Properties of Nonsteroidal Antiinflammatory Drugs (NSAIDs) and Selective COX-2 Inhibitors Using Sensitive Microsomal and Platelet Assays. Can. J. Physiol. Pharmacol. 1997, 75, 1088.
27. Brideau, C.; Kargman, S.; Liu, S.; Dallob, A. L.; Enrich, E. W.; Rodger, I. W.; Chan, C.-C. A Human Whole Blood Assay for Clinical Evaluation of Biochemical Efficacy of Cyclooxygenase Inhibitors. Inflamm. Res. 1996, 45, 68-74.
28. Chan, C.-C.; Boyce, S.; Brideau, C.; Ford-Hutchinson, A. W.; Gordon, R.; Guay, D.; Hill, R.; Li, C.-S.; Mancini, J.; Penneton, M.; Prasit, P.; Rasori, R.; Riendeau, D.; Roy, P.; Targari, P.; Vickers, P.; Wong, E.; Rodger, I. W. Pharmacology of a Selective Cyclooxygenase-2 Inhibitor L-745,337: A Novel Nonsteroidal Antiinflammatory Agent with an Ulcerogenic Sparing Effect in Rat and Nonhuman Primate Stomach. J. Pharmacol. Exp. Ther. 1905, 274, 1531.
29. 2-Phenyl-4-methyl-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one and 2-phenyl-4,4′-dimethyl-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one were 1.1 and 7.9 μM, respectively, against COX-2 in the human whole blood assay. Merck Frosst Centre for Therapeutic Research, unpublished results.
30. 2-Phenyl-5,5′-dimethyl-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten- 1-one was 1.3 μM against COX-1 in the human whole blood assay: Merck Frosst Centre for Therapeutic Research, unpublished results.
31. Stephen O'Keefe, Merck Research Laboratories, Rahway, NJ, unpublished results.
32. Christine Brideau, Merck Frosst Centre for Therapeutic Research, unpublished results.
33. David M. Percival, Marc Ouellet, and Jean-Pierre Falgueyret, Merck Frosst Centre for Therapeutic Research, unpublished results. These data were obtained by methods previously published for other COX-2-selective inhibitors: see refs 5a and 7b.
34. (a) van Arman, C. G. Pathway to Adjuvant Arthritis. Fed. Proc. 1976, 35, 2442.
35. (b) Taurog, J. D.; Argentieri, D. C.; McReynolds, R. A. Adjuvant Arthritis. Methods Enzymol. 1988, 162, 339-350.